Updates and Statements

01.30.2023

Pfizer and International Trachoma Initiative Deliver One Billionth Zithromax® Dose Toward Trachoma Elimination by 2030

01.27.2023

Pfizer Responds to Research Claims

01.27.2023

Pfizer Receives Positive CHMP Opinion for Conversion of PAXLOVID™ Conditional Marketing Authorization to Full Marketing Authorization in the European Union

01.17.2023

Pfizer to Acquire Sanford, North Carolina Manufacturing Site from Abzena

12.22.2022

Hospira, Inc. Issues A Voluntary Nationwide Recall For One Lot of Vancomycin Hydrochloride Injection, USP 1.5g/vial, Due To The Presence of Visible Glass Particulates

12.20.2022

U.S. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™

12.13.2022

Pfizer to Provide U.S. Government with an Additional 3.7 Million Treatment Courses of PAXLOVID™ to Help Combat COVID-19

12.09.2022

Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza

11.23.2022

Pfizer Signs Agreement to Provide the European Union with PAXLOVID™

11.16.2022

Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection

11.03.2022

Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19

10.28.2022

Safety Recommendation on Janus kinase (JAK) Inhibitors Issued in the European Union